SCHEMBL6651872

SCHEMBL6651872

CN(C)CCOC(F)c1ccc(Cc2nccn2C)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.36
CHRM2 P08172 3/20 0.36
SLC6A2 P23975 3/20 0.36
SLC6A4 P31645 3/20 0.36
SLC6A3 Q01959 3/20 0.36
CYP2D6 P10635 3/20 0.36
ADRA2B P18089 2/20 0.36
HRH1 P35367 2/20 0.36
KCNH2 Q12809 2/20 0.36
HRH3 Q9Y5N1 2/20 0.36
CYP2C19 P33261 2/20 0.36
LTA4H P09960 1/20 0.35
ADRA2A P08913 2/20 0.34
CHRM1 P11229 2/20 0.34
OPRM1 P35372 2/20 0.34
DRD3 P35462 2/20 0.34
CYP1A2 P05177 2/20 0.34
CHRM4 P08173 1/20 0.34
CHRM5 P08912 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6650451 0.87 LMNA (0.39) LMNACHRM2SLC6A2SLC6A4SLC6A3
SCHEMBL6654163 0.80 HRH3 (0.35) LMNACHRM2SLC6A2SLC6A4SLC6A3
SCHEMBL6648700 0.77 HRH3 (0.35) CHRM2SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL6672328 0.76 TRPM5 (0.32) LMNACHRM2SLC6A2SLC6A4SLC6A3
SCHEMBL6650409 0.75 L3MBTL1 (0.40) CYP2D6TSHROPRK1MEN1KMT2A
SCHEMBL6649435 0.75 OPRK1 (0.37) LMNACHRM2SLC6A2SLC6A4SLC6A3
SCHEMBL21721828 0.73 HTR1D (0.43) TSHROPRK1MEN1KMT2AL3MBTL1
SCHEMBL6649371 0.73 HTR1A (0.32) LMNAHTR2CCHRNB2CHRNA4HTR1A
SCHEMBL6650639 0.72 POLB (0.39) LMNACHRM2SLC6A2SLC6A4SLC6A3
SCHEMBL6650689 0.70 L3MBTL1 (0.40) LMNACYP2D6CYP2C19CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1103243-B1 UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES FOR THE TREATMENT OF TROUBLES MEDIATED BY AN EXCESS OF SUBSTANCE P ESTEVE LABOR DR (ES) 2004-01-07 EP claimed